Human cardiovascular progenitor cells

ABSTRACT

The present invention provides populations of human cardiovascular progenitor cells, methods of making such cells, and methods of using the cells for production of populations of cardiovascular colonies and populations of cardiomyocytes. Methods of cardiomyocytes replacement therapy are also provided.

CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional Application No.61/040,049 filed Mar. 27, 2008.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

This invention was made with government support under grant numbersHL071800 and GM075019 awarded by the National Institutes of Health. Thegovernment has certain rights in the invention.

BACKGROUND OF THE INVENTION

During embryonic development, the tissues of the body are formed fromthree major cell populations: ectoderm, mesoderm and definitiveendoderm. These cell populations, also known as primary germ celllayers, are formed through a process known as gastrulation. Followinggastrulation, each primary germ cell layer generates a specific set ofcell populations and tissues. Mesoderm gives rise to blood cells,endothelial cells, cardiac and skeletal muscle, and adipocytes.Definitive endoderm generates liver, pancreas and lung. Ectoderm givesrise to the nervous system, skin and adrenal tissues. The process oftissue development from these germ cell layers involves multipledifferentiation steps, reflecting complex molecular changes. Withrespect to mesoderm and its derivatives, three distinct stages have beendefined. The first is the induction of mesoderm from cells within astructure known as the epiblast. The newly formed mesoderm, also knownas nascent mesoderm, migrates to different positions that will be sitesof future tissue development in the early embryo. This process, known aspatterning, entails some molecular changes that are likely reflective ofthe initial stages of differentiation towards specific tissues. Thefinal stage, known as specification, involves the generation of distincttissues from the patterned mesodermal subpopulations.

Evidence suggests that mesoderm is induced in successive waves whichrepresent subpopulations with distinct developmental potential. Themesoderm that is formed first migrates to the extraembryonic region andgives rise to hematopoietic and endothelial cells, whereas the nextpopulation migrates anteriorly in the developing embryo and contributesto the heart and cranial mesenchyme. These lineage relationships weredefined initially through histological analysis and have been largelyconfirmed by cell tracing studies. With respect to hematopoieticcommitment, there is now compelling evidence from studies with the EScell differentiation model and on the mouse embryo that the earliestidentifiable progenitor is a cell that also displays vascular potential,a cell that is known as the hemangioblast (Choi et al. (1998);Development 125:725-732; Huber et al. (2004) Nature 432:625-30).Analysis of this progenitor revealed that it co-expresses the mesodermgene brachyury and the receptor tyrosine kinase Flk-1, indicating thatit represents a subpopulation of mesoderm undergoing commitment to thehematopoietic and vascular lineages (Fehling et al. (2003) Development130:4217-4227). Lineage-tracing studies have demonstrated that the heartdevelops from a Flk-1⁺ population, suggesting that a comparablemultipotential cell may exist for the cardiovascular system (Ema et al.(2006) Blood 107:111-117). Analyses of ES cell differentiation cultureshave provided evidence for the existence of a Flk-1⁺ progenitor withcardiac and endothelial potential (Yamashita et al. (2005) FASEB19:1534-1536). Recent studies also support the existence of murinecardiovascular progenitors that may give rise to multiple cardiovascularlineages. (Kattman et al. (2006) Dev. Cell 11:723-732; Moretti et al.(2006) Cell 127:1151-1165; Wu et al. (2006) Cell 127:1137-1150). A humancardiovascular progenitor population has not heretofore been identified.

SUMMARY OF THE INVENTION

The present invention provides enriched populations of humancardiovascular progenitor cells. The human cardiovascular progenitorcells are characterized by the presence of the cell surface marker KDRand the absence of the cell surface marker C-KIT. The humancardiovascular progenitor cells are capable of differentiating intocardiomyocytes, endothelial cells and vascular smooth muscle cells invitro and in vivo.

In another embodiment, the present invention provides methods ofproducing human cardiovascular progenitor cells from human embryoidbodies (EBs) comprising culturing the EBs in the presence of an activinand a bone morphogenic factor (BMP) and optionally basic FibroblastGrowth Factor (bFGF), and subsequently culturing in the presence of aninhibitor of the Wnt growth factor and optionally vascular endothelialgrowth factor (VEGF) to provide human cardiovascular progenitor cells,and harvesting the cells from the cell culture.

In another embodiment, the present invention provides a method ofgenerating a population of cells containing at least about 30% andpreferably at least about 40%, and more preferably at least about 50%human cardiomyocytes comprising culturing the human cardiovascularprogenitor cells in the presence of an inhibitor of Wnt and optionallyVEGF. In one embodiment, the cells are cultured as monolayers. Inanother embodiment, the cells are cultured as aggregates. The presenceof cardiomyocytes may be determined by assessing contractile activity ofcells or by measuring expression of genes indicative of cardiomyocytes,such as for example cardiac troponin T (CTNT).

The present invention further provides a method of generating humancardiovascular colonies containing cardiomyocytes, endothelial cells andvascular smooth muscle cells comprising culturing the humancardiovascular progenitor cells in the presence of VEGF, bFGF, and aninhibitor of Wnt. In a preferred embodiment, the cells are cultured inmethylcellulose.

The human cardiovascular precursor cells and the differentiated cellsderived therefrom are useful in methods of screening for agents thataffect cardiovascular progenitors, cardiomyocytes, endothelial cells,vascular smooth muscle cells, and cardiovascular tissue.

The human cardiovascular precursor cells are also useful for expansionand storage and as a source of cardiomyocytes, endothelial cells andvascular smooth muscle cells.

The human cardiovascular precursor cells and the differentiated cellsderived therefrom are also useful in methods of improving orreconstituting cardiac function in a mammal, and for engineeringcardiovascular tissue in vitro for transplantation.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an outline of a protocol used to direct differentiation ofhuman embryonic stem cells (hESC) to the cardiac lineage in accordancewith one embodiment of the present invention.

FIG. 2 shows the kinetics of CTNT⁺ cell development in EBs induced witha combination of BMP4, bFGF and activin A. EBs were harvested at theindicated time points and analyzed by intracellular flow cytometry forthe frequency of cells expressing CTNT.

FIG. 3 shows the frequency of CTNT⁺ cells in day 14 EBs followingmanipulation of the Wnt signaling pathway at different stages.

FIG. 4 shows the frequency of CTNT⁺ cells in day 14 EBs followingculture in combinations of BMP4, activin A and bFGF during the inductionstage.

FIG. 5 shows the total number of CTNT⁺ cells per well of 24 well platesfor day 14 EBs treated with the indicated combinations of VEGF and DKKI.For FIGS. 1-5, bars represent the standard error or the means of threeindependent experiments. Statistical analysis was performed with theunpaired t-test. *P=0.07, **P<0.01, ***P<0.001.

FIG. 6 shows gene expression analysis of EBs at different stages ofdevelopment.

FIG. 7 shows flow cytometric analysis of different aged EBs.

FIGS. 8a-h show quantitative RT-PCR gene analysis of the threepopulations isolated from day 6 EBs.

FIG. 9 shows cardiac potential of the three day 6 populations.

FIG. 10 shows the cardiac potential of the day 6 KDR^(low)/C-KIT^(neg)population.

FIGS. 11a-j show quantitative RT-PCR expression analysis of adherentpopulations generated from the day 6 EB-derived KDR^(low)/C-KIT^(neg)fraction.

FIG. 12 shows an analysis for the presence of CTNT⁺, CD31⁺ and SMA⁺cells following 10-12 days of culture of the KDR^(low)/C-KIT^(neg)population.

FIG. 13 depicts an expression analysis of 4-day-old cardiovascularcolonies isolated from mixed RFP/GFP cultures.

FIG. 14 depicts a cell dose response showing the relationship betweenthe number of KDR^(low)/C-KIT^(neg)-derived cells plated and the numberof cardiovascular colonies that develop.

FIG. 15 depicts exemplar traces showing whole-cell voltage clamprecordings of transient outward K+ current (I_(to)) natively expressedin KDR^(low)/C-KIT^(neg)-derived cardiomyocytes.

FIG. 16 shows mean current density-voltage relationship for cells as inFIG. 15. From a batch of 10 cells, 8 showed the I_(to) current and themean+/−SEM current densities were plotted using traces from these 8cells.

FIG. 17 shows mean time-to-peak current (solid squares) and inactivationτ (open squares) for cells as in FIG. 16 (n=8).

FIG. 18 shows electrical activity for KDR^(low)/C-KIT^(neg) cellsisolated from day 6 EBs that were cultured in the MEA (MultiChannelSystems) dish for 2-3 weeks. Extracellular electrical activitywas recorded with or without 1 μM quinidine (Sigma).

FIG. 19 is a model depicting development of the cardiovascularprogenitors in hESC cultures.

FIG. 20 shows images of undifferentiated hES2 cells, day 4 EBs and day14 EBs with contracting cardiomyocytes (magnification×200).

FIG. 21 shows the kinetics of the development of CTNT⁺ cells in EBs.

FIG. 22 shows the kinetics of the development of contracting EBs inducedwith the protocol in FIG. 1. Between 150-200 EBs were scored at eachtime point for the presence of contracting EBs. Bars represent standarderror of the mean of three independent experiments.

FIG. 23 shows the total number of cells per well of 24 well plates inday 14 EBs following induction with the combinations of factorsindicated below the graph.

FIG. 24 shows the total number of CTNT⁺ cells per well of 24 well platesin day 14 EBs following induction with the combinations of factorsindicated below the graph.

FIG. 25 shows the frequency of CTNT⁺ cells from day 14 EBs treated withthe indicated combinations of VEGF and DKK.

FIG. 26 shows the total number of CTNT⁺ cells per well of 24 well platesfor day 14 EBs treated with the indicated combinations of VEGF and DKK.For FIGS. 23-26, bars represent standard error of the mean of threeindependent experiments. Statistical analysis was performed withunpaired t-text. *P<0.05, **P<0.01

FIGS. 27a-g show quantitative RT-PCR analysis of three populationsisolated from day 6 EBs. Average expression normalized to cyclophinin isshown. Bars represent standard error of the mean of three independentexperiments.

FIG. 28 is a graph of relative cell numbers after 10-14 days inmonolayer culture of KDR^(low)/C-KIT^(neg) populations isolated from day6 EBs. 40,000 cells per well of 96 well plates were induced with thecombinations of factors shown below the graph. Bars represent standarderror of the mean of three independent experiments.

FIG. 29 shows flow cytometric analysis demonstrating the emergence ofthe three different KDR/C-KIT populations in EBs generated from H1 hESC.

FIG. 30 shows the development of CTNT+ cells from the H1 hESC-derivedKDR^(low)/C-KIT^(neg) fraction following 7 days of culture.

FIGS. 31a-i show quantitative RT-PCR expression analysis ofKDR^(low)/C-KIT^(neg)-derived adherent populations cultured in thepresence of VEGF (10 ng/mL), DKK1 (150 ng/mL) and bFGF (10 ng/mL).Cultures were harvested at the specified times and analyzed for theexpression of the indicated genes. Average expression normalized tocyclophinin is shown.

FIG. 32 shows expression analysis of individual 4-day-old cardiovascularcolonies generated from the hES2-derived KDR^(low)/C-KIT^(neg)population.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides populations of human cardiovascularprogenitor cells. The human cardiovascular progenitor cells of thepresent invention are capable of differentiation, under appropriateconditions, into cardiomyocytes, endothelial cells, and vascular smoothmuscle cells. The human cardiovascular progenitor cells arecharacterized by the expression of the tyrosine kinase receptor KDR andby the lack of expression of the tyrosine kinase receptor C-KIT.

In one embodiment of the invention, the human cardiovascular progenitorcells a r e obtained from embryoid bodies (EBs). EBs are threedimensional colonies that contain developing populations from a broadspectrum of lineages. Conditions for formation of EBs from embryonicstem cells (ESC) are known in the art. For example, human ESC maintainedon embryonic feeder cells may be depleted of feeders, for example byculturing on a layer of basement membrane matrix such as Matrigel™ (BDBiosciences, Bedford, Mass.), dissociated to form small clusters andplated in serum free media in the presence of a BMP. In one preferredembodiment of the invention, feeder-depleted human ESC are cultured inserum free media in the presence of BMP4 for about one day to form EBs.In another preferred embodiment, the concentration of BMP4 is from about0.1 ng/mL to about 1.0 ng/mL, and more preferably about 0.5 ng/mL.

Human ESC may be obtained commercially or by methods known in the art.For example, human ESC may be prepared from blastocysts by methods knownin the art and disclosed for example in U.S. Pat. No. 5,843,780 toThomson et al. and by Reubinoff et al. (2000) Nature Biotech 18:399.

EBs may also be formed from induced pluripotent stem (iPS) cells bymethods known in the art and disclosed, for example, by Takahashi et al.(2007) Cell 131:861 and Mali et al. (2008) Stem Cells 26:1998.

The human cardiovascular precursor cells of the present invention may beobtained by culturing human EBs in serum free media in the presence ofan activin and a BMP, subsequently culturing in the presence of aninhibitor of Wnt to provide a population of cardiovascular progenitorcells, and optionally harvesting the cells from culture and furtheroptionally enriching the harvested cell population for cardiovascularprogenitor cells. In preferred embodiments the activin is activin A, theBMP is BMP4, and the inhibitor of Wnt is Dickkopf-1 (DKK-1).

Another embodiment of the present invention provides a method forproducing human cardiovascular precursor cells comprising culturinghuman EBs in serum free media in the presence of activin A and BMP4 andoptionally bFGF for about one to about four days, and subsequentlyculturing the cells in serum free media in the presence of DKK-1 andoptionally VEGF for about one to two days, harvesting the population ofcells, and optionally enriching the population for human cardiovascularprogenitor cells.

In a preferred embodiment the EBs are cultured in the presence ofactivin A and BMP4 and optionally bFGF for about four days. Theconcentrations of activin A, BMP4 and optionally bFGF are sufficient toinduce a primitive streak-like population of cells characterized by theupregulation of expression of T and WNT3A. In the subsequent step, theconcentrations of DKK-1 and optionally VEGF are sufficient to provide apopulation of cardiovascular progenitor cells.

In a preferred embodiment, the concentration of activin A is from about0.5 ng/mL to about 30 ng/mL, and more preferably from about 1.0 ng/mL toabout 5.0 ng/mL. In a most preferred embodiment the concentration ofactivin A is about 3.0 ng/mL.

In a preferred embodiment, the concentration of BMP4 is from about 1.0ng/mL to about 20.0 ng/mL, and more preferably from about 5.0 ng/mL toabout 15 ng/mL. In a most preferred embodiment, the concentration ofBMP4 is about 10 ng/mL.

In a preferred embodiment, the concentration of bFGF is from about 1.0ng/mL to about 10.0 ng/mL, and more preferably from about 3.0 ng/mL toabout 6.0 ng/mL. In a most preferred embodiment, the concentration ofbFGF is about 5.0 ng/mL.

In a preferred embodiment, the concentration of DKK1 is from about 100ng/mL to about 200 ng/mL, and more preferably from about 125 ng/mL toabout 175 ng/mL. In a most preferred embodiment, the concentration ofDKK1 is about 150 ng/mL.

In another preferred embodiment, the concentration of VEGF is from about1.0 ng/mL to about 50.0 ng/mL, and more preferably from about 1.0 ng/mLto about 25.0 ng/mL. In a most preferred embodiment, the concentrationof VEGF is about 10.0 ng/mL.

In another preferred embodiment of the present invention, human EBs arecultured in serum free media for about four days in the presence ofabout 3.0 ng/mL of activin A, about 10.0 ng/mL of BMP4 and about 5.0ng/mL of bFGF, at which time about 150 ng/mL of DKK1 and about 10.0ng/mL of VEGF are added and cells are cultured for about one to two daysto produce cardiovascular progenitor cells. In another preferredembodiment, the population is enriched for cardiovascular progenitorcells, for example by sorting for cells that express KDR and do notexpress C-KIT. In a preferred embodiment, the sorting is byimmunoselection, for example by flow cytometry.

In another embodiment, the present invention provides a method ofgenerating a population of human cardiomyocytes comprising culturing thehuman cardiovascular progenitor cells in the presence of an inhibitor ofWnt and optionally VEGF for about seven to about 10 days, and harvestinga population of human cardiomyocytes from culture. In a preferredembodiment, the inhibitor of Wnt is DKK1, and the preferredconcentrations of DKK1 and VEGF are as described hereinabove. In onepreferred embodiment, the cells are plated as monolayers ingelatin-coated wells. In another embodiment, the cells are cultured inlow cluster dishes as aggregates. The populations of humancardiomyocytes contain at least about 30%, and preferably at least about40%, and more preferably at least about 50% cardiomyocytes. In otherembodiments, the populations of human cardiomyocytes contain at leastabout 70%, and preferably at least about 80% and more preferably atleast about 90% and up to 100% cardiomyocytes. The cardiomyocytes may beidentified by assessing contractile activity or by measuring expressionof genes indicative of cardiomyocytes, such as for example CTNT.

The human cardiovascular progenitor cells of the present invention arealso useful for generating subpopulations of cardiomyocytes including,for example, atrial, ventricular, and pacemaker cells, usingdifferentiation conditions known to those of skill in the art.

In another embodiment, the present invention provides a method ofgenerating cardiovascular colonies containing cardiomyocytes,endothelial cells, and vascular smooth muscle cells comprising culturingthe human cardiovascular precursor cells in the presence of VEGF, bFGFand an inhibitor of Wnt, preferably DKK1, for about three to about sevendays. In a preferred embodiment, the cells are plated inmethylcellulose. The preferred concentrations of VEGF, bFGF and DKK areas described hereinabove. The presence of cardiomyocytes, endothelialcells, and vascular smooth muscle cells can be determined by measuringexpression of genes indicative of cardiomyocytes, such as CTNT, andgenes indicative of endothelial cells, such as CD31, VE-CADHERIN andgenes indicative of vascular smooth muscle cells, such as SMA andCALPONIN.

The present invention further provides methods for screening for agentsthat have an effect on human cardiovascular progenitor cells,cardiovascular colonies, cardiomyocytes, endothelial cells and vascularsmooth muscle cells. The method comprises contacting cells from one ofthe cell populations described hereinabove with a candidate agent, anddetermining whether the agent has an effect on the cell population. Theagent to be tested may be natural or synthetic, one compound or amixture, a small molecule or polymer including polypeptides,polysaccharides, polynucleotides and the like, an antibody or fragmentthereof, a compound from a library of natural or synthetic compounds, acompound obtained from rational drug design, a condition such as a cellculture condition, or any agent the effect of which on the cellpopulation may be assessed using assays known in the art. The effect onthe cell population may be determined by any standard assay forphenotype or activity, including for example an assay for markerexpression, receptor binding, contractile activity, electrophysiology,cell viability, survival, morphology, or DNA synthesis or repair.Standard proliferation and differentiation assays are described in U.S.Pat. No. 6,110,739. Such agents are useful for the control of cellgrowth, differentiation and survival in vivo and in vitro, and tissuemaintenance, regeneration and repair.

The present invention further provides compositions comprisingpopulations of human cardiovascular precursor cells and compositionscomprising populations of human cardiovascular colonies. Thecompositions may comprise pharmaceutically acceptable carriers anddiluents. The compositions may further comprise components thatfacilitate engraftment. Compositions comprising these populations areuseful for cell and tissue replacement and repair, and for generatingpopulations of cardiomyocytes, endothelial cells, and vascular smoothmuscle cells in vitro and in vivo. Compositions comprising humancardiovascular progenitor cells are useful for expansion of theprogenitor populations. The compositions may be formulated as amedicament or delivery device for treating a cardiac condition.

In another embodiment, the present invention provides methods of cellreplacement and methods of tissue replacement useful for treatment ofdisorders characterized by insufficient cardiac function including, forexample, congenital heart disease, coronary heart disease,cardiomyopathy, endocarditis and congestive heart failure. Both thedifferentiated cells and the cardiovascular progenitor cells are usefulfor replacement therapy, since the progenitor populations are capable ofdifferentiation to the cardiomyocyte, endothelial and vascular smoothmuscle lineages in vivo. The cells are also useful for generatingcardiovascular tissue in vitro. Methods for engineering cardiac tissueare known in the art and reviewed for example by Birla in “Stem CellTherapy and Tissue Engineering for Cardiovascular Repair” Springer,2006.

Accordingly, in one embodiment the present invention provides a methodof cardiomyocyte replacement therapy comprising administering to asubject in need of such treatment a composition comprisingcardiomyocytes isolated from a cell population enriched for humancardiovascular progenitor cells obtained in accordance with the presentinvention. In another embodiment, the present invention provides amethod of treating a disorder characterized by insufficient cardiacfunction comprising administering to a subject in need of such treatmenta composition comprising human cardiovascular progenitor cells. In apreferred embodiment, the subject is a human. The composition may beadministered by a route that results in delivery to or migration tocardiac tissue including, for example, injection or implantation, andunder conditions that result in a reduction of at least one adverseeffect or symptom or the disorder.

All references cited herein are incorporated herein in their entirety.

The following examples serve to further illustrate the presentinvention.

Example 1 Materials and Methods

Maintenance of Human ES Cells

H1 (NIH code WA01) from WiCell Research Institute (Madison, Wis.) andhES2 (NIH code ES02) from ESI International (Singapore) were maintainedon irradiated mouse embryonic feeder cells in hESC media consisting ofDulbecco's Modified Eagle Medium (DMEM)/F12 (50:50; Mediatech, Herndon,Va.) supplemented with 20% knock-out serum replacement (SR), 100 μMnonessential amino acids, 2 mM glutamine, 50 U/mL penicillin, 50 μg/mLstreptomycin (Invitrogen, Grand Island, N.Y.), 10⁻⁴ M β-mercaptoethanol(Sigma, St Louis, Mo.) and 20 ng/mL hbFGF (R&D Systems, Minneapolis,Minn.) in 6-well tissue culture plates. The AAVS1-targeted hES2 cellline was generated by co-infection of parental hES2 cells with 10⁶ viralparticles of both, AAV2-TRUF11 (CAG-GFP-TK-neo) and wild type AAV2.After G418 selection, GFP positive cells were sorted and subclones wereisolated. Targeted integration of the transgenes was confirmed byligation-mediated polymerase chain reaction (LM PCR). Wild type AAVsequences were not detected in GFP positive clones. RFP expressing hEScells were generated by targeting the RFP cDNA to the Rosa26 locus ofhES2 cells as described by Irion et al. (2007) Nat. Biotechnol.12:1477-1482.

Differentiation of Human ES Cells

Prior to the generation of EBs, hESCs were cultured on a layer ofMatrigel (BD Biosciences, Bedford, Mass.) to deplete the feeders for 48hours. Cells from the Matrigel culture were dissociated to smallclusters by 20-minute treatment with collagenase B (1 mg/mL; Roche,Indianapolis, Ind.) followed by a 2-minute treatment with trypsin-EDTA(0.05%). From day 0-1, EBs were plated in 2 mL basic media (StemPro-34(Invitrogen), 2 mM glutamine, 4×10⁻⁴ M monothioglycerol (MTG), and 50μg/mL ascorbic acid (Sigma) plus 0.5 ng/mL BMP4 (R&D Systems). Thefollowing concentrations of factors were used for EB formation, mesoderminduction and cardiac specification: BMP4:10 ng/mL, hbFGF: 5 ng/mL,ActivinA: 3 ng/ml, hDKK1:150 ng/mL, hVEGF: 10 ng/mL. The factors wereadded with the following sequence: day 1-4, BMP4, hbFGF and ActivinA;day 4-8, VEGF and DKK1; following day 8, VEGF, DKK1, and bFGF. Themedium was changed every 4 days beyond day 8. All human factors andinhibitors were purchased from R&D Systems (Minneapolis, Minn.).Cultures were maintained in a 5% CO₂, 5% O₂, and 90% N₂ environment forthe first 10-12 days of culture and then in 5% CO₂/air environment forthe following days.

Flow Cytometry Sorting and Tube Formation on Matrigel

EBs were harvested and dissociated to single cells with trypsin (0.25%trypsin-EDTA). Following trypsinization, analyses were carried out usingFacscalibur flow cytometer (Becton Dickinson). Cells were sorted using aMoFlo (Dako Cytomation, Fort Collins, Colo.) cell sorter. Flowcytometric data were analyzed using the FlowJo (Treestar, San Carlos,Calif.) software programs. Anti-KDR-PE, anti-C-KIT-APC were purchasedfrom R&D Systems. Sorted KDR^(low)/C-KIT^(neg) population wasdifferentiated in Stempro34 medium supplemented with VEGF (25 ng/ml) andbFGF (25 ng/ml). Tube-like structures were formed within 24 hours aftertransferred to Matrigel-coated glass coverslips.

Immunofluorescence

Dissociated cells were cultured on glass cover slips for 2 days. At thispoint the cells were fixed with 4% PFA and then stained. The followingantibodies were used for immunostaining: Anti-human CD31, anti-humanVE-Cadherin from R&D Systems, anti-mouse Troponin T and anti-humanSmooth Muscle Actin from Lab Vision (Freemont, Calif.), anti-human ANP,Connexin 43 and anti-human α/β MHC antibodies from Chemicon (Temecula,Calif.), and anti-human α-Actinin from Sigma (St. Louis, Mo.).Anti-human smooth muscle myosin heavy chain (SMHC), Caldesmon, VonWillebrand Factor antibodies were purchased from DakoCytomation(Carpinteria, Calif.). The Cy2, Cy3 and Cy5 conjugated second antibodieswere obtained from Jackson ImmunoResearch (West Grove, Pa.).Fluorescence was visualized using a Leica DMRA2 fluorescence microscope(Leica, Wetzlar, Germany), and images were recorded using a digitalHamamatsu CCD camera (Hamamatsu City, Japan).

Colony Assays

To generate cardiovascular colonies, KDR^(low)/C-KIT^(neg) cellsisolated from day 6 EBs were aggregated in the presence of VEGF (25ng/mL), bFGF (10 ng/ml) and DKK1 (150 ng/ml) for 2-3 days. At thisstage, the aggregates were dissociated and the cells were cultured inmethylcellulose containing VEGF (25 ng/mL), bFGF (25 ng/ml) and DKK1(150 ng/ml) in a 5% CO₂, 5% O₂, and 90% N₂ environment. Colonies werescored following 4-6 days of cultures for the colony frequency analysis.

RT-PCR

For expression studies, individual colonies were isolated from themethylcellulose cultures and analyzed using a modified version of theprotocol previously described by Brady et al. (1993) Methods Enzymol.225:611-623. The amplified cDNA was then subjected to normal PCR.Real-time quantitative PCR was performed on the MasterCycler EP RealPlex(Eppendort). Experiments were done in triplicate using Platinum SYBRGreenER qPCR SuperMix (Invitrogen). All primers are described in TableI. All annealing reactions were carried out at 60° C.

TABLE 1 GENE FORWARD PRIMER REVERSE PRIMER Primers for Normal PCRT(Brachyury) tgt ccc agg tgg ctt aca gat gaa ggt gtg cca aag ttg cca atacac (SEQ ID NO: 1) (SEQ ID NO: 2) WNT3A aat gcc act gca tct tcc act ggttgg tga cag ttc ctt gct gtc tga (SEQ ID NO: 3) (SEQ ID NO: 4) DKK1 tctcag tgt ggc act tac ctg t cca aga gat cct tgc gtt cta gac t (SEQ ID NO:5) (SEQ ID NO: 6) KDR cct cta ctc cag taa acc tga ttg gg tgt tcc cag catttc aca cta tgg (SEQ ID NO: 7) (SEQ ID NO: 8) ISL1 cac aag cgt ctc gggatt gtg ttt agt ggc aag tct tcc gac aa (SEQ ID NO: 9) (SEQ ID NO: 10)NKX2.5 gcg att atg cag cgt gca atg agt aac ata aat acg ggt ggg tgc gtg(SEQ ID NO: 11) (SEQ ID NO: 12) TBX20 gaa aga cca cac agc ctc att gcttca atg tca gtg agc ctg gag gaa (SEQ ID NO: 13) (SEQ ID NO: 14) GFP ttctcg gcc aca agc tgg aat aca act ggg tgg aca ggt aat ggt tgt (SEQ ID NO:15) (SEQ ID NO: 16) RFP acc tgg tgg agt tca aga cca tct acc tct aca aatgtg gta tgg ctg (SEQ ID NO: 17) (SEQ ID NO: 18) CD31 atc att tct agc gcatgg cct ggt att tgt gga ggg cga ggt cat aga (SEQ ID NO: 19) (SEQ ID NO:20) β-ACTIN ttt gaa tga tga gcc ttc gtc ccc ggt ctc aag tca gtg tac aggtaa gc (SEQ ID NO: 21) (SEQ ID NO: 22) Primers for both Normal PCR andQPCR OCT4 aac ctg gag ttt gtg cca ggg ttt tga act tca cct tcc ctc caacca (SEQ ID NO: 23) (SEQ ID NO: 24) C-KIT att ccc ag ccc atg agt cct tgaaca cgt gga aca cca aca tcc t (SEQ ID NO: 25) (SEQ ID NO: 26) CALPONINaag gac gca ctg agc aac gct att acg cca ctg tca cat cca cat agt (SEQ IDNO: 27) (SEQ ID NO: 28) TBX5 aaa tga aac cca gca tag gag ctg gc aca ctcagc ctc aca tct tac cct (SEQ ID NO: 29) (SEQ ID NO: 30) CTNT ttc acc aaagat ctg ctc ctc gct tta tta ctg gtg tgg agt ggg tgt gg (SEQ ID NO: 31)(SEQ ID NO: 32) MLC2A aca tca tca ccc acg gag aag aga att gga aca tggcct ctg gat gga (SEQ ID NO: 33) (SEQ ID NO: 34) VE-CAD tgg aga agt ggcatc agt caa cag tct aca atc cct tgc agt gtg ag (SEQ ID NO: 35) (SEQ IDNO: 36) SMA aat act ctg tct gga tcg gtg gct acg agt cag agc ttt ggc taggaa (SEQ ID NO: 37) (SEQ ID NO: 38) NFATC ttg acc tga act cgt gcc ttagga ggc ctt cag gtt gtt tct ttc cgt (SEQ ID NO: 39) (SEQ ID NO: 40) NEUDccc atg gtg ggt tgt cat ata ttc atg t cca gca tca cat ctc aaa cag cac(SEQ ID NO: 41) (SEQ ID NO: 42) Primers for QPCR CD31 tct atg acc tcgccc tcc aca aa gaa cgg tgt ctt cag gtt ggt att tca (SEQ ID NO: 43) (SEQID NO: 44) ISL1 ttg tac ggg atc aaa tgc gcc aag agg cca cac agc gga aaca (SEQ ID NO: 45) (SEQ ID NO: 46) NKX2.5 acc tca aca gct ccc tga ctc tata atc gcc gcc aca aac tct cc (SEQ ID NO: 47) (SEQ ID NO: 48) TBX20 gtctct cag ctc ctg ggt atc atc tt tgt tgc tat gga tgc tgt gct ggt (SEQ IDNO: 49) (SEQ ID NO: 50) MEOX1 tgg aag cgt gtg aag gga ggt aag gaa gagggt gaa ggt ggg att g (SEQ ID NO: 51) (SEQ ID NO: 52) NRG1 agt tca gctcct tcc acc aca ac cgt ttc ata ctc ctc atc ctc cac tat cc (SEQ ID NO:53) (SEQ ID NO: 54) PAX6 tcg aag ggc caa atg gag aag aga ag ggt ggg ttgtgg aat tgg ttg gta ga (SEQ ID NO: 55) (SEQ ID NO: 56) SOX1 cct gtg tgtacc ctg gag ttt ctg t tgc acg aag cac ctg caa taa gat g (SEQ ID NO: 57)(SEQ ID NO: 58) GATA1 tgt cag taa acg ggc agg tac tca ata cca tcc ttccgc atg gtc agt (SEQ ID NO: 59) (SEQ ID NO: 60) SOX17 agg aaa tcc tcagac tcc tgg gtt ccc aaa ctg ttc aag tgg cag aca (SEQ ID NO: 61) (SEQ IDNO: 62) FOXA2 gca ttc cca atc ttg aca cgg tga gcc ctt gca gcc aga atacac att (SEQ ID NO: 63) (SEQ ID NO: 64) FOXA3 ttg gcc atg tcg tca ccattc tct ccc aca ccc taa cca gcc ttt (SEQ ID NO: 65) (SEQ ID NO: 66) KDRact ttg gaa gac aga acc aaa tta tct c tgg gca cca ttc cac ca (SEQ ID NO:67) (SEQ ID NO: 68) T cag tgg cag tct cag gtt aag aag ga cgc tac tgc aggtgt gag caa (SEQ ID NO: 69) (SEQ ID NO: 70) CYCLOPHININ gaa gag tgc gatcaa gaa ccc atg ac gtc tct cct cct tct cct cct atc ttt act t (SEQ ID NO:71) (SEQ ID NO: 72)In Vivo Analyses of KDR^(low)/C-KIT^(neg)-Derived Populations

KDR^(low)/C-KIT^(neg) cells derived from GFP expressing hESC werecultured in the presence of VEGF (10 ng/mL), bFGF (10 ng/ml) and DKK1(150 ng/ml) for 5-10 days before transplantation. NOD/SCID-gamma micewere anesthetized, intubated, and 100,000 donor cells were injecteddirectly into the left ventricular wall in an open-chest procedure.Hearts were harvested 2-11 weeks post surgery, fixed in 1%paraformaldehyde in cacodylate buffer, and vibrotome-sectioned at 300um. Grafted regions were identified and cryo-sectioned at 10 um.Immuno-histochemistry was done for GFP antibody (Chemicon, AB3080,1:100; Vector ABC and DAB kits), α-actinin antibody (Sigma, A7811,1:500; Chemicon AQ300R secondary antibody, 1:20), CD31 antibody (Dako,M0823, 1:50; Vector ABC and DAB kits), and smooth muscle MHC antibody(Biomedical Technologies, BT-562, 1:300; Alexa 555 secondary antibody,1:200). Confocal images were analyzed for colocalization using ImageJand Pierre Bourdoncle's plugin with default settings. For evaluation inthe murine infarct model, myocardial infarction was induced in SCIDbeige mice via direct coronary ligation, using techniques described byRubert et al. (2007) Nature Biotechnol. 25:993-994. Ten to twentyminutes later the mice were injected with 500,000KDR^(low)/C-KIT^(neg)-derived cells (n=9) or an equivalent volume ofserum free cell media (n=12). All injections were attempted in theborder zone of the infarct. Two weeks later assessment of ventricularfunction was performed using 9.4 Tesla Magnetic Resonance Imaging.

Patch Clamp

Whole cell patch clamp recordings were performed at room temperatureusing an IX50 inverted microscope (Olympus), a Multiclamp 700AAmplifier, a Digidata 1300 Analogue/Digital converter and a PC withpClamp9.1 software (Axon Instruments, Foster City, Calif.). Bathsolution was (in mM): NaCl 136, KCl 4, CaCl₂ 1, MgCl₂ 2, CoCl₂ 5,HEPES10, glucose 10, and tetrodotoxin (TTX) 0.02 (pH 7.4). Pipettes wereof 3-5 _(M)′Ω resistance when filled with intracellular solutioncontaining (in mM): KCI 135, EGTA 10, HEPES10, and glucose 5 (pH 7.2).Cells were stepped from a holding potential of −80 mV to test potentialsfrom −80 mV to +40 mV in 20 mV increments, before a −30 mV tail pulse(durations as in FIG. 4). Data were analyzed using pClamp9.1 software(Axon Instruments). Current amplitudes were normalized to cell size(whole-cell membrane capacitance). Inactivation τ values were calculatedusing a single exponential fit of current decay.

Field Potential Recording

KDR^(low)/C-KIT^(neg) cells isolated from day 6 EBs were cultured in theMEA (Multi ChannelSystems) dish with StemPro-34 plus 10 ng/mL VEGF and150 ng/mL DKK1 for 2-4 weeks. 2 days before recording, cells werechanged to DMEM (Cell grow) with 15% FBS. Extracellular electricalactivity was simultaneously recorded from 60 channels and analyzed withsoftware MC Rack (Multi Channel Systems).

Example 2 Regulation of Cardiac Development in hESC DifferentiationCultures

To direct the differentiation of hESC to the cardiac lineage, a stagedprotocol was designed that involves the induction of a primitivestreak-like population, the patterning of cardiac mesoderm and thespecification of the cardiovascular lineages using combinations of BMP4,activin A, VEGF, bFGF and DKK1, factors known to play a role in mesoderminduction and cardiac specification in different model systems. Anoutline of the protocol is shown in FIG. 1. With the protocolexemplified here, hESC were first differentiated in the presence of BMP4for 24 hours to allow the formation of EBs. The combination of activinand BMP4 at stage 1 induced a primitive streak-like population andmesoderm as demonstrated by the upregulation and transient expression ofT (Brachyury) and WNT3a, genes known to be expressed in thesepopulations in the mouse (FIG. 6). At stage 2, VEGF and the Wntinhibitor DKK1 further patterned the mesoderm and promoted the expansionand maturation of KDR+ progenitor population. bFGF was added again atday 8 of differentiation to support the continued expansion of thedeveloping cardiovascular lineages. This protocol supports cardiacdevelopment within the EBs as demonstrated by the emergence ofcontracting cells and cells that expressed cardiac troponin T (CTNT)(FIG. 2), α-actinin, a/β myosin heavy chain, ANP and connexin 43 (FIGS.20, 21). The highest frequency of CTNT+ cells was routinely observedbetween days 14 and 16 of culture (FIGS. 2, 21) although this populationcould be maintained within the EBs over a two-month period. The kineticsof development of contracting EBs paralleled the emergence of the CTNT+population (FIG. 22).

Example 3 Role of Wnt Signaling on Emergence of Cardiac Lineage fromHuman ES Cells

The role of Wnt signaling pathway on emergence of the cardiac lineagefrom the human ES cells was investigated, specifically focusing on thatstage beyond primitive streak induction (Stage2). EBs were induced inthe presence of BMP4, bFGF and activin A as outlined in the protocol.Either Wnt3A or DKK1 were added to the cultures at the days indicated inFIG. 3. These factors were maintained in the cultures throughout the14-day period. VEGF and bFGF were added at the indicated times. At day14, the EBs were harvested and analyzed as above. The control wascultures that did not receive WNT or DKK1. Addition of DKK1 to the EBsat day 4 of differentiation led to a more than two-fold increase in thefrequency of CTNT+ cells (up to 40%) at day 14 of culture (FIG. 3). Theeffect of DKK1 was less pronounced if added at day 6 or 8 and there wasno enhancement of the frequency of CTNT+ cells if the addition wasdelayed to day 10 of differentiation. Wnt3A had the opposite effect andcompletely suppressed development of CTNT+ cells if added to thecultures at days 4 or 6. These findings indicate that stage-specificinhibition of the canonical Wnt pathway is necessary to promote cardiacspecification of the BMP4/activin induced PS population.

Example 4 Role of BMP4, Activin A and bFGF in Induction of the CardiacLineage

To evaluate the role of BMP4, activin A and bFGF in the induction of thecardiac lineage in hESC differentiation cultures, single factors as wellas different combinations were tested during the induction stage (days1-4). At day 4 the factors were removed and the EBs treated as outlinedin FIG. 1. Day 4-14 EBs were treated with combinations of VEGF and DKK1indicated in FIGS. 5, 25, and 26, with addition of bFGF after day 8. EBswere harvested at day 14 and analyzed for frequency of CTNT⁺ cells foreach combination and for total number of CTNT⁺ cells per well of 24 wellplates. BMP4, bFGF or activin A alone or the combinations of BMP4 andFGF or activin A and bFGF were poor inducers of cardiac development asdemonstrated by the low frequency (FIG. 4) and total number of CTNT+cells generated (FIGS. 23, 24). While BMP4 and activin A did inducesignificant numbers of CTNT+ cells, the combination of the 3 factors wasthe most potent and generated the highest frequency and total number ofcardiac cells, routinely yielding cultures consisting of between 40% and50% CTNT+ cells. While VEGF was not essential for cardiac development,the addition of 10 ng/ml of this factor did increase the total number ofCTNT+ cells that developed. Increasing concentrations of VEGF above thisconcentration reduced the cell number in the cultures, resulting in asignificant decrease in the total number of CTNT+ cells generated (FIGS.5, 25 and 26).

Molecular analysis of the developing EBs revealed dynamic changes inexpression patterns following the establishment of a primitivestreak-like population. Together with T and WNT3A, expression of DKK1was upregulated early and persisted through the 18-day time course (FIG.6). Expression of endogenous DKK1, between days 2 and 4 ofdifferentiation, may function to specify cardiac mesoderm, resulting inthe establishment of the cardiac lineage in the absence of the additionof exogenous inhibitor (FIG. 3). KDR was expressed in undifferentiatedES cells. The levels of expression appeared to increase between days 4and 6 and then persisted for the next 12 days. ISL1, a gene that marksprogenitors of the secondary heart field in the early embryo, wasexpressed in the EBs between days 6 and 8, preceding the expression ofthe cardiac transcription factor Nkx2.5 that was first detected at day 8of differentiation. Expression of two TBX transcription factors requiredfor proper cardiac development TBX5, and TBX20, as well as thecontractile proteins MLC2A and CTNT was upregulated between days 8 and10 of differentiation, reflecting the onset of cardiac development.

Example 5 Identification of the KDR^(low)/C-KIT^(neg) EB Population withCardiovascular Potential

Developing EBs were analyzed for expression of KDR and C-KIT. C-KIT wasused as a potential marker to define distinct populations as itsexpression in mouse EBs identifies the earliest hemangioblast-derivedhematopoietic and vascular progenitors as well as the anterior primitivestreak and the developing endoderm. FIG. 7 shows flow cytometricanalysis of different aged EBs. As shown in FIG. 7, three distinctpopulations, KDR^(high)/C-K1T⁺, KDR^(low)/C-KIT^(neg) andKDR^(neg)/C-KIT⁺ can be resolved within the day 6 EBs. Development ofthe three populations was dependent on induction with both BMP4 andactivin A (not shown). The three populations were isolated by cellsorting and analyzed for gene expression patterns and cardiac potential.FIG. 8 shows quantitative RT-PCR gene expression analysis of the threepopulations isolated from day 6 EBs. Average expression was normalizedto cyclophinin. The KDR^(high)/C-KIT⁺ population expressed CD3I,VE-CADHERIN and SMA, genes associated with vascular development, as wellas GATA-I, a gene indicative of hematopoietic commitment (FIGS. 8, 27).Genes involved in cardiac development, including NKX2.5, ISL1 and TBX5were expressed at highest levels in the KDR^(low)/C-KIT^(neg) fraction.This fraction also expressed SMA, very low levels of GATA-1, but nodetectable VE-CADHERIN or CD31. As SMA is expressed early in the cardiaclineage as well as in the VSM lineage, this expression could reflect theonset of cardiac development. The KDR^(neg)/C-KIT⁺ cells expressed thehighest levels of OCT4 and T of the 3 fractions, indicating the presenceof residual undifferentiated ES cells as well as primitive streak-likecells. The relatively high levels of FOXA2 and SOX17 in this fractionsuggest that it also contains cells undergoing commitment to theendoderm lineage. SOX1 and PAX6 were only detected at very low levels,suggesting little, if any, differentiation to the neuroectoderm lineagein the EBs at this stage of development (FIG. 27). Taken together, theseexpression patterns demonstrate that the KDR^(high)/C-KIT⁺ populationcontains hematopoietic and vascular progenitors, theKDR^(low)/C-KIT^(neg) population contains cardiac progenitors and theKDR^(neg)/C-KIT⁺ population consists of a mixture of undifferentiated EScells, primitive streak cells and endodermal cells.

To monitor cardiac potential, the cells were plated either as monolayerson gelatin coated wells or allowed to reaggregate in low cluster dishesand cultured as aggregates. Specifically, cells were isolated from day 6EBs and cultured on gelatin-coated wells as monolayers with VEGF (10ng/ml), DKK1 (150 ng/ml) and bFGF (10 ng/ml). CTNT⁺ cells were analyzedafter 10 days culture. Results are shown in FIG. 9.KDR^(low)/C-KIT^(neg) cells from day 6 EBs were sorted and cultured as amonolayer or as aggregates in low cluster wells with VEGF (10 ng/ml) andDKK1 (150 ng/ml). Cultures were harvested and analyzed for the presenceof CTNT⁺ cells following 7-10 days of differentiation. Results are shownin FIG. 10. The numbers (%) represent the mean+/− standard error ofthree independent experiments. Bars represent standard error of the meanof three independent experiments. Statistic analysis was performed withunpaired t-test. *P<0.01, ***P<0.001. The KDR^(low)/C-KIT^(neg)population displayed the greatest cardiomyocyte potential (FIG. 9) andreadily generated CTNT+ cells and populations of contracting cells inboth the aggregates in suspension cultures as well as in the adherentmonolayers (FIG. 10). Approximately 40% of the cells within theaggregates were CTNT+ whereas greater than 50% of the monolayer culturesconsistently expressed this marker. The high frequency of cardiomyocytesin the monolayer cultures routinely led to the development of sheets ofcells contracting as a synchronous mass. The isolatedKDR^(low)/C-KIT^(neg) cells expanded approximately 1.5-fold asaggregates (data not shown) and 3-fold in the monolayer cultures (FIG.28). With the induction protocol and sorting strategy outlined, anoutput of 1 cardiomyocyte per 4 input hESC was estimated. In a typicalexperiment, 2×10⁶ hESC generated 1×10⁶ day 6 EB cells of which 30%(3.0×905 cells) represented the KDR^(low)/C-KIT^(neg) fraction. Thispopulation expanded 3-fold (1×10⁶ cells) in the monolayer culture formatto yield a population that consisted of approximately 50% cardiomyocytes(5×10⁵). Kinetic analysis of EBs generated from a second hESC line, H1demonstrated the development of the 3 KDR/C-KIT populations at day 5rather that day 6 of differentiation. Analysis of the day 5KDR^(low)/C-KIT^(neg) population indicated that it also displayedcardiac potential (FIGS. 29, 30).

Example 6 Characterization of KDR^(low)/C-KIT^(neg)-Derived Lineages

Quantitative RT-PCR expression analysis of adherent populationsgenerated from the day 6 EB-derived KDR^(low)/C-KIT^(neg) fractionplated with VEGF (10 ng/ml), DKK1 (150 ng/ml) and bFGF (10 ng/ml) wasperformed. Cultures were harvested at the indicated days in FIG. 11 andthe cells were analyzed for expression (D7 represents populations oneday following plating). Average expression normalized to CYCLOPHININ isshown. Bars represent standard error of the mean of three independentexperiments.

Expression analysis (qPCR) of KDR^(low)/C-KIT^(neg)-derived adherentpopulations at different days following plating demonstrated theupregulation of genes associated with endothelial (CD31, VE-CADHERIA),VSM (CALPONIN, SMA), cardiac development (NKX2.5, ISL1, TBX5, TBX20) andcardiac maturation (CTNT, MLC2A) (FIGS. 11, 31). Expression of NFATC andNeuregulin 1 (NRG1) suggest the presence of endocardium in the cultures.The low levels of NEUD, PAX6, SOX1, FOXA2, FOXA3, SOX17 and MEOX1expression indicate that the cultures are not contaminated withneuroectoderm, endoderm or somatic mesoderm (FIGS. 11, 31).

KDR^(low)/C-KIT^(neg) cells were isolated from day 6 EBs and cultured asa monolayer with the different combinations of factors indicated belowthe graph in FIG. 12. Cells were harvested and analyzed for the presenceof CTNT+, CD31+ and SMA+ cells following 10-12 days culture. SMAantibody can stain both cardiomyocytes and smooth muscle cells. Thenumber (%) represent standard error of the mean of three independentexperiments.

Flow cytometric analysis of KDR^(low)/C-KIT^(neg)-derived adherent cellscultured for 10-12 days in VEGF and DKK1 revealed that almost 90%expressed SMA, 50% expressed CTNT and 4% expressed CD31 (FIG. 12).Addition of bFGF to the cultures reduced the proportion of CTNT+ cellsto 30% and increased the CD31+ population to 30%. The proportion of SMA+cells decreased modestly to an average of 80% in the presence of bFGF.The addition of bFGF did not significantly influence the cell number inthe monolayer cultures (FIG. 28). These findings clearly indicate thatthe majority of cells within KDR^(low)/C-KIT^(neg)-derived populationare of the cardiovascular lineages. They also show that bFGF caninfluence the proportion of cardiomyocytes and endothelial cells thatdevelop in this population.

Immunostaining analysis of the KDR^(low)/C-KIT^(neg)-derived populationcultured in VEGF, DKK1 and bFGF demonstrated the presence of CD31+,VE-Cadherin+ and von Willebrand Factor+ endothelial cells, of CTNT+cardiomyocytes and of SMA+, SMHC+ and Caldesmon+ cells indicative of VSMdevelopment. The immature cardiomyocytes within the population expressedboth CTNT and SMA, whereas the VSM cells expressed only SMA. To furthercharacterize the KDR^(low)/C-KIT^(neg)-derived endothelial cells, thepopulation was expanded in the presence of VEGF and bFGF and thencultured on Matrigel-coated cover slips. Under these conditions thecells formed a lattice indicative of endothelial cell organization intotube-like structures. The cells within these structures expressed CD31and displayed the capacity to take up Dil-AC-LDL confirming theirendothelial phenotype. The findings from the immunostaining analysis areconsistent with those from the flow cytometric studies and demonstratethat the KDR^(low)/C-K1T^(neg)-derived population consists of cells ofthe cardiac, endothelial and vascular smooth muscle lineages.

KDR^(low)/C-K1T^(neg)-derived cells were also transplanted into thehearts of NOD/SCID mice to document their developmental potential invivo. A GFP expressing version of the hES2 cell line was used for thesestudies. Histological analyses revealed the presence of GFP+ cells inthe hearts following transplantation. Detection of GFP with an antibodyidentified the same population as visualized by epifluorescence,indicating that the GFP signal represents the presence of donor cellsand does not result from background fluorescence. GFP+ populationsco-expressing either α-actinin, CD31 or SMHC were detected in thegrafts, indicating differentiation to the cardiac, endothelial andvascular smooth muscle lineages in vivo. Teratomas were not detected inany of the transplanted animals (N>10). To further evaluate the in vivopotential of this population, KDR^(low)/C-KIT^(neg)-derived cells weretransplanted directly into infarcted hearts of SCID beige mice. Whenanalyzed 2 weeks later, animals transplanted with theKDR^(low)/C-KIT^(neg)-derived cardiovascular population had a 31% higherejection fraction than those injected with media alone (56%+/−3.6% vs39%+/−4.8%, p=0.008). These findings are consistent with previousreports and demonstrate that transplantation of hESC-derivedcardiomyocytes leads to improvement in cardiac function in rodent modelsof myocardial infarction.

Example 7 Identification and Characterization of CardiovascularColony-Forming Cells

When plated in methylcellulose in the presence of VEGF, bFGF and DKK1,KDR^(low)/C-KIT^(neg)-derived cells generated small compact colonieswithin 4 days of culture. PCR analysis of individual 4-day-old coloniesdemonstrated co-expression of markers indicative of cardiac (CTNT),vascular (CD31 and/or VE-CADHERIN) and VSM (SMA and/or CALPONIN)development (FIGS. 13, 32). When maintained in culture for a further 6days, a portion of these colonies generated contracting cells,confirming that they contain cardiomyocytes. ISL1 and TBX5 weretypically not expressed in the same colonies, suggesting that theirexpression may define colonies that contain distinct subpopulations ofdeveloping cardiac cells from different heart fields. Immunostaining ofadherent populations from individual colonies grown on cover slipsrevealed the presence of SMA+, CTNT+ and VE-CAD+ cells, confirming thatthese colonies do have cardiac, endothelial and VSM potentials.

Two different approaches were used to determine if the cardiovascularcolonies are clonal. First, KDR^(low)/C-KIT^(neg)-derived cells from GFPexpressing hESC were mixed in the methycellulose assay withKDR^(low)/C-KIT^(neg)-derived cells from hESC engineered to express redfluorescent protein (RFP) in the methycellulose colony assay. Coloniesanalyzed 4 days later were found to express either GFP or RFP but notboth (FIG. 13), a finding consistent with the interpretation that theyarise from a single cell and do not form as a result of cellaggregation. As a second approach, a cell dose response experiment wasperformed, in which different numbers of KDR^(low)/C-KIT^(neg)-derivedcells were plated in the cardiac methylcellulose cultures. Therelationship between the number of colonies that develop and the numberof cells plated was linear, with a slope approaching one, furthersupporting the notion that the colonies are derived from a single cell(FIG. 14). Taken together, these findings indicate that these coloniesrepresent clones of cardiovascular cells derived from a cardiovascularcolony-forming cell (hCV-CFC).

Functional potential of KDR^(low)/C-KIT^(neg)-derived cardiomyocytes wasevaluated with whole-cell current and field potential measurements. Inwhole-cell voltage clamp analysis, 80% of cells studied expressed apredominant voltage-gated, transient outward potassium current (FIGS.15, 16). The voltage dependence, density and gating kinetics of thiscurrent (FIGS. 16, 17) resembled that of the I_(to) potassium currentfound in human atrial and ventricular myocytes. Field potentialsrecorded from cultured cells using microelectrodes revealed that thehuman cardiovascular progenitors derived cardiac cells were electricallycoupled to one another. In addition, as expected, the Vaugn Williamsclass la agent quinidine decreased the measured T wave amplitude andincreased the QT interval (FIG. 19).

The invention claimed is:
 1. An isolated population of humancardiovascular progenitor cells derived from human pluripotent stemcells in vitro, wherein the progenitor cells express KDR and do notexpress C-KIT and VE-CADHERIN and wherein the progenitor cells areprogenitors of cardiomyocytes, endothelial cells, and vascular smoothmuscle cells.
 2. The population of human cardiovascular progenitor cellsof claim 1 obtained by culturing human embryoid bodies in serum freemedia in the presence of activin and BMP.
 3. The population of claim 2wherein activin is activin A.
 4. The population of claim 2 wherein BMPis BMP4.
 5. A composition comprising the isolated population of humancardiovascular progenitor cells of claim 1.